Novo Nordisk A/S (NYSE:NVO) Shares Sold by Carnegie Investment Counsel

Carnegie Investment Counsel lowered its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 7.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 198,545 shares of the company's stock after selling 14,949 shares during the period. Carnegie Investment Counsel's holdings in Novo Nordisk A/S were worth $17,079,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of NVO. Hennion & Walsh Asset Management Inc. raised its stake in Novo Nordisk A/S by 9.4% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 19,742 shares of the company's stock valued at $1,698,000 after buying an additional 1,701 shares during the last quarter. StrongBox Wealth LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $282,000. Carolina Wealth Advisors LLC boosted its stake in Novo Nordisk A/S by 308.9% in the 4th quarter. Carolina Wealth Advisors LLC now owns 1,656 shares of the company's stock worth $142,000 after purchasing an additional 1,251 shares in the last quarter. Essex Savings Bank grew its position in Novo Nordisk A/S by 8.0% during the 4th quarter. Essex Savings Bank now owns 9,636 shares of the company's stock worth $829,000 after purchasing an additional 715 shares during the last quarter. Finally, Sendero Wealth Management LLC increased its stake in Novo Nordisk A/S by 35.4% during the 4th quarter. Sendero Wealth Management LLC now owns 46,413 shares of the company's stock valued at $3,992,000 after purchasing an additional 12,142 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NVO traded down $4.33 during midday trading on Friday, hitting $78.74. 21,239,835 shares of the company traded hands, compared to its average volume of 9,296,463. The company has a market capitalization of $353.33 billion, a price-to-earnings ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45. The business has a 50 day simple moving average of $98.33 and a two-hundred day simple moving average of $117.69. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on NVO. Cantor Fitzgerald reissued an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Sunday, December 29th. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.